NYSE - Delayed Quote • USD
Annovis Bio, Inc. (ANVS)
At close: 4:00 PM EDT
After hours: 6:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.47 | -0.29 | -1.2 | -1.83 |
| Low Estimate | -0.55 | -0.4 | -1.36 | -2.57 |
| High Estimate | -0.36 | -0.15 | -1.05 | -1.32 |
| Year Ago EPS | -1.07 | -1.63 | -6.23 | -1.2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.14 | -1.09 | -1.3 | -0.8 |
| EPS Actual | -1.07 | -1.63 | -2.24 | -0.72 |
| Difference | 0.07 | -0.54 | -0.94 | 0.08 |
| Surprise % | 6.10% | -49.50% | -72.30% | 10.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.47 | -0.29 | -1.2 | -1.83 |
| 7 Days Ago | -0.47 | -0.29 | -1.2 | -1.83 |
| 30 Days Ago | -0.45 | -0.5 | -2.06 | -2.52 |
| 60 Days Ago | -0.72 | -0.77 | -3.1 | -3.02 |
| 90 Days Ago | -0.72 | -0.77 | -3.1 | -3.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | 1 | 2 | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ANVS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 56.10% | -- | -- | 7.90% |
| Next Qtr. | 82.20% | -- | -- | 10.20% |
| Current Year | 80.70% | -- | -- | 4.80% |
| Next Year | -52.50% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 4/30/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/30/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/21/2024 |
| Downgrade | Brookline Capital: Buy to Hold | 2/28/2024 |
Related Tickers
AVXL Anavex Life Sciences Corp.
4.0700
+1.75%
SAVA Cassava Sciences, Inc.
21.67
-0.21%
CADL Candel Therapeutics, Inc.
8.55
+9.62%
ALT Altimmune, Inc.
6.97
-4.91%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.3800
-9.80%
VSTM Verastem, Inc.
4.0200
-2.43%
IBRX ImmunityBio, Inc.
6.62
+1.53%
ANNX Annexon, Inc.
4.9600
0.00%
ACIU AC Immune SA
3.8700
+9.32%
IOVA Iovance Biotherapeutics, Inc.
9.70
-3.10%